1. Adelaide Research & Scholarship

Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 33 (Search time: 0.004 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2007Cetuximab for the treatment of colorectal cancerJonker, D.; O'Callaghan, C.; Karapetis, C.; Zalcberg, J.; Tu, D.; Au, H.; Berry, S.; Krahn, M.; Price, T.; Simes, R.; Tebbutt, N.; van Hazel, G.; Wierzbicki, R.; Langer, C.; Moore, M.
2021Pre- And postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCDSchmoll, H.J.; Stein, A.; van Cutsem, E.; Price, T.; Hofheinz, R.D.; Nordlinger, B.; Daisne, J.F.; Janssens, J.; Brenner, B.; Reinel, H.; Hollerbach, S.; Caca, K.; Fauth, F.; Hannig, C.V.; Zalcberg, J.; Tebbutt, N.; Mauer, M.E.; Marreaud, S.; Lutz, M.P.; Haustermans, K.
2015Detection and clinical significance of circulating tumor cells in colorectal cancer - 20 years of progressHardingham, J.; Grover, P.; Winter, M.; Hewett, P.; Price, T.; Thierry, B.
2014The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Sommeijer, D.; Karapetis, C.; Zalcberg, J.; Tu, D.; Jonker, D.; Simes, J.; Tebbutt, N.; Yip, D.; Price, T.; O'Callaghan, C.
2018Liver resection for colorectal cancer metastases: a comparison of outcomes over time in South AustraliaSultana, A.; Meng, R.; Piantadosi, C.; Brooke-Smith, M.; Chen, J.; Dolan, P.; Maddern, G.; Price, T.; Padbury, R.
2015Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literatureChan, D.; Pavlakis, N.; Shapiro, J.; Price, T.; Karapetis, C.; Tebbutt, N.; Segelov, E.; Rosell, R.
2022Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolitesLiu, Z.; Martin, J.H.; Liauw, W.; McLachlan, S.A.; Link, E.; Matera, A.; Thompson, M.; Jefford, M.; Hicks, R.J.; Cullinane, C.; Hatzimihalis, A.; Campbell, I.; Crowley, S.; Beale, P.J.; Karapetis, C.S.; Price, T.; Burge, M.E.; Michael, M.
2013Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC clinical trials group and AGITG co.Siu, L.; Shapiro, J.; Jonker, D.; Karapetis, C.; Zalcberg, J.; Simes, J.; Couture, F.; Moore, M.; Price, T.; Siddiqui, J.; Nott, L.; Charpentier, D.; Liauw, W.; Sawyer, M.; Jefford, M.; Magoski, N.; Haydon, A.; Walters, I.; Ringash, J.; Tu, D.; et al.
2013The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumorsRosen, L.; Lipton, L.; Price, T.; Belman, N.; Boccia, R.; Hurwitz, H.; Stephenson Jr, J.; Wirth, L.; McCoy, S.; Hei, Y.; Hsu, C.; Tebbutt, N.
2015Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerPrice, T.; Bruhn, M.; Lee, C.; Hardingham, J.; Townsend, A.; Mann, K.; Simes, J.; Weickhardt, A.; Wrin, J.; Wilson, K.; Gebski, V.; Van Hazel, G.; Robinson, B.; Cunningham, D.; Tebbutt, N.

Discover